The EPS projection of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for quarter ended 2016-09-30 is $1.1. Last week, the projection for EPS was $1.1 against target of $1.1, a month earlier. While 2-months ago, this projection was $1.1 versus forecast of $1.1a quarter months earlier, posting a deviation of 0%.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 0, and 0, correspondingly.
The per-share earnings downgrade for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 0, and 1, in that order.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EPS target was $1.1 for the quarter closed 1. It was based on 3 calls. As on 2016-04-28 the EPS was $0.87. The change was $-0.04, posting a deviation of -4.4%. The price projections gave a standard deviation of 0.09.
Quarterly Sales Estimates
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) sales prediction for the fiscal 2016 stands at $835.149 and the median estimate is at $830.767. Almost 7 analysts gave sales target.
Among this, the highest sales estimate is $854 while the lowest target is $825.09 showing standard deviation of 10.569%.
As many as 7 analysts have positive sales targets revision while 7 reduced sales estimates, posting a deviation of 0.137%.
Last month, 7 experts have positive sales number revision. Also, 7 research groups lowered the sales projections, posting a deviation of -0.191%.
A quarter ago, 7 hiked sales target and 7 reduced sales forecast, posting a deviation of -1.807%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...